Clariant’s Masterbatches address challenges of India’s pharma and construction industries
- Clariant at PlastIndia – Booth D6, Hall no 10R
- New masterbatch range targeted for use in production of pharma containers for parenteral, ocular and nasal drugs
- New Construction insulation offers maximum energy savings with minimal material input
Dr. Deepak Parikh, Region Head – India, Middle East and Africa said, "Our commitment to sustainability, innovation and our employee is a true differentiator for us to stay ahead in the competitive and dynamic global market scenario. And now, with the announcement of the Make In India campaign, we as a strong, transforming organization are fully geared up to support it. We are accelerating change and will continue to deliver on our hyper growth strategy in 2015, fulfilling our commitments to all our stakeholders, as India’s attractive market stays at the core of Clariant’s global focus."
Mr. Sandeep Puri, Head – Masterbatches, Clariant in India said, "Pharma and construction – two significant industries in India, are at the core of Clariant’s innovation pipeline. And now, with Clariant’s broader footprint in India in terms of Masterbatches production, distribution and sales in India, we are fully geared up to support these burgeoning industries."
Mr. Gregor Keil, Head - Regional Marketing & Key Account Management, Masterbatches, India, Middle East, Africa, Clariant International, added, "Clariant Masterbatches has repositioned itself toward a more innovation-driven business, with a focus on emerging markets as a key element of its strategy. India, with its attractive trends, is one of the most important regions Clariant is focusing on globally."
In focus: REMAFIN-EP
At PlastIndia 2015, Clariant is highlighting its new ‘REMAFIN-EP’ range of polyethylene (PE) and polypropylene (PP)-based masterbatches. This range of white masterbatches and compounds is targeted for use in production of pharmaceutical containers for parenteral, ocular, and nasal drugs. It complements a range of colors and additives for medical devices and pharmaceutical packaging introduced under Clariant’s MEVOPUR® brand.
"As the pharmaceutical industry globally is increasingly looking to India to manufacture and source high-quality, cost-effective products, the packaging technology needs to meet strict global standards. This will create new possibilities for our customers to improve the sustainability offering and overall performance of their finished products," added Mr. Keil.
The differentiator of these products is that its raw materials have undergone stringent testing to comply with global regulations, including US Pharmacopeia 87, 88 and European Pharmacopeia EP 3.1.3 standard. This product helps support innovative use of materials to enhance packaging processes and protect pharmaceutical products.
In focus: Hydrocerol
Clariant’s range of Hydrocerol chemical foaming agents will address the need gap in the construction market for energy-reduction insulation materials within thinner, space-saving boards.
Existing buildings are responsible for almost 40% of global CO2 emissions, while valuable space is lost through thick insulation panels used in today’s constructions.
Clariant’s Hydrocerol-based masterbatches enable foaming of lightweight polystyrene at significantly smaller size than the currently known foams. Also, the optimized foam structure has excellent insulation properties. As a result, manufacturers will be able to produce strong and light insulation boards with improved properties that will also enable maximum living space, and contribute to saving material use and production costs. The products also support products that can meet energy saving regulations.
Clariant India has local masterbatch production activities at Rania, Kalol and Nandesari (Gujarat) and Vashere (Maharashtra) sites in India.
Clariant in is showcasing its solutions at PlastIndia 2015, Booth D6, Hall no 10R.